The Association Between Different Monocyte Subsets and Coronary Collateral Development

This study has been completed.

Sponsor:

Information provided by:

Yuksek Ihtisas Hospital

ClinicalTrials.gov Identifier:

NCT01356836

First received: May 17, 2011

Last updated: May 19, 2011

Last verified: March 2011

History of Changes

Tracking Information
First Received Date ^ICMJE	May 17, 2011
Last Updated Date	May 19, 2011
Start Date ^ICMJE	January 2011
Primary Completion Date	May 2011 (final data collection date for primary outcome measure)
Current Primary Outcome Measures ^ICMJE	Not Provided
Original Primary Outcome Measures ^ICMJE	Not Provided
Change History	Complete list of historical versions of study NCT01356836 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures ^ICMJE	Not Provided
Original Secondary Outcome Measures ^ICMJE	Not Provided
Current Other Outcome Measures ^ICMJE	Not Provided
Original Other Outcome Measures ^ICMJE	Not Provided

Descriptive Information
Brief Title ^ICMJE	The Association Between Different Monocyte Subsets and Coronary Collateral Development
Official Title ^ICMJE	Not Provided
Brief Summary	Collateral growth and coronary angiogenesis are chronic adaptations to myocardial ischemia. Collateralization helps to restore blood flow and as a result salvages myocardium in severely ischemic myocardial regions. Thus, good collateral development in patients with severe coronary artery disease (CAD) improves ventricular function and prognosis (1-3). However, coronary collateral development is different among patients even with similar degrees of coronary artery stenosis. Several factors, such as diabetes mellitus (4) and duration of myocardial ischemic symptoms (5) have been reported to effect coronary collateral development. At the cellular level, inflammatory cells, especially monocytes have an important role in collateralization. In a series of experimental studies with animals, it has been shown that monocytes are important elements for development of collateral vessels (6-7). In a recent study, it has been demonstrated that increased circulating monocyte count is related to good collateral development in patients with stable coronary artery disease (8). Monocytes in human blood are heterogeneous and can be classified into two subsets according to the presence or absence of the FcγRIII receptor CD16 (9): CD14++CD16- monocytes characterized by high level expression of the CD14 cell surface receptor but no expression of CD16 receptor, and CD14+CD16+ monocytes characterized by the co-expression of CD16 receptor with either high or low level expression of the CD14 receptor. These subsets differ in function and response to several cytokines. Our aim in this study was to find out any possible relationship between the levels of circulating monocyte subsets and coronary collateral development.
Detailed Description	Not Provided
Study Type ^ICMJE	Observational
Study Design ^ICMJE	Observational Model: Cohort Time Perspective: Prospective
Target Follow-Up Duration	Not Provided
Biospecimen	Not Provided
Sampling Method	Non-Probability Sample
Study Population	Consecutive patients who were found to have >95% stenosis of at least one major coronary artery in their first coronary angiogram were included in this study.
Condition ^ICMJE	Coronary Artery Disease Coronary Ischemia
Intervention ^ICMJE	Not Provided
Study Group/Cohort (s)	Good-poor collateral Patients who had good and poor collaterals formed 2 groups Good collateral, Poor collateral
Publications *	Not Provided
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.

Recruitment Information
Recruitment Status ^ICMJE	Completed
Enrollment ^ICMJE	105
Completion Date	May 2011
Primary Completion Date	May 2011 (final data collection date for primary outcome measure)
Eligibility Criteria ^ICMJE	Inclusion Criteria: > 95% stenosis of at least one major coronary artery in their first coronary angiogram Exclusion Criteria: previous percutaneous or surgical revascularization history evidence of ongoing infection and inflammation known malignancy and chronic kidney disease (serum creatinine > 1.5 mg/dl diabetic patients
Gender	Both
Ages	18 Years to 80 Years
Accepts Healthy Volunteers	No
Contacts ^ICMJE	Contact information is only displayed when the study is recruiting subjects
Location Countries ^ICMJE	Turkey

Administrative Information
NCT Number ^ICMJE	NCT01356836
Other Study ID Numbers ^ICMJE	Monocyte subsets
Has Data Monitoring Committee	Yes
Responsible Party	Türkiye Yüksek İhtisas Education and Research Hospital, Specialist of Cardiology
Study Sponsor ^ICMJE	Yuksek Ihtisas Hospital
Collaborators ^ICMJE	Not Provided
Investigators ^ICMJE	Not Provided
Information Provided By	Yuksek Ihtisas Hospital
Verification Date	March 2011
^ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP

To Top